摘要
目的:比较地西他滨与阿扎胞苷治疗骨髓增生异常综合征(MDS)的疗效。方法:选取2019年1月—2022年1月于我院接受治疗的86例MDS患者作为研究对象,根据抛币法将患者随机分为对照组和观察组,每组43例。对照组接受地西他滨(DAC)治疗,观察组接受阿扎胞苷(AZA)治疗,比较两组临床疗效、预后危险度、C反应蛋白(CRP)水平、降钙素原(PCT)水平、全血红细胞沉降率(ESR)水平、骨髓原始细胞比例、不良反应发生情况。结果:两组临床总有效率、预后危险度比较,差异无统计学意义(P>0.05);两组治疗前、后CRP、PCT、ESR水平及骨髓原始细胞比例比较,差异无统计学意义(P>0.05),但两组治疗后CRP、PCT、ESR水平及骨髓原始细胞比例优于治疗前(P<0.05);观察组不良反应总发生率低于对照组(P<0.05)。结论:AZA和DAC治疗MDS患者的临床治疗效果、预后危险度、感染指标改善程度、骨髓原始细胞比例上升程度方面均无明显差异,但AZA产生的不良反应更少。
Objective:To compare the efficacy of decitabine with azacitidine in the treatment of myelodysplastic syndromes(MDS).Methods:Eighty-six patients with myelodysplastic syndrome treated in our hospital from January 2019 to January 2022 were selected as study subjects,and the patients were randomly divided into control and observation groups according to the coin flip method,with 43 cases in each group.The control group received decitabine(DAC)treatment and the observation group received azacitidine(AZA)treatment,and the clinical eficacy,prognostic risk,C-reactive protein(CRP)level,calcitoninogen(PCT)level,whole blood erythrocyte sedimentation rate(ESR)level,bone marrow primitive cell ratio,and the occurrence of adverse reactions were compared between the two groups.Results:There was no significant difference in the total clinical effective rate and prognostic risk between the two groups(P>0.05).There was no significant difference in the levels of CRP,PCT,ESR and the proportion of bone marrow primordial cells between the two groups before and after treatment(P>0.05),but the levels of CRP,PCT,ESR and the proportion of bone marrow primordial cells in the two groups after treatment were better than those before treatment(P<0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).Conclusion:There were no significant differences in clinical outcomes,prognostic risk,improvement in infection indicators,or increase in bone marrow primitive cell ratio between AZA and DAC-treated MDS patients,but AZA produced fewer adverse effects.
作者
李卓
关红梅
LI Zhuo;GUAN Hongmei(Department of Hematology,Nanyang Second General Hospital,Nanyang 473000,Henan,China)
出处
《中国药物滥用防治杂志》
CAS
2023年第3期470-473,477,共5页
Chinese Journal of Drug Abuse Prevention and Treatment
